Validation of Steroid-Sparing Therapy in Patients Receiving Oxaliplatin-based Chemotherapy: A before-and-after Prospective Observational Study

Volume 26, Issue 10, October 2025, Pages 3623-3628

Yoshihiro Yamamoto; Norio Watanabe; Aoi Goshima; Hiroki Hayashi; Tomohiro Fukuoka; Motozumi Ando; Masami Kawahara

• View Article
• PDF 394.67 K

Prognostic Value of PKM2 Expression in de novo Metastatic Colorectal Cancer Patients

Volume 26, Issue 9, September 2025, Pages 3485-3493

Ahmed Refaat; Nada Mohammad Hussien; Rabab Mohamed Mumdouh Farghaly; Marwa T. Hussien; Abeer Ibrahim

• View Article
• PDF 862.71 K

Efficacy of Exercise Rehabilitation Program in Relieving Oxaliplatin Induced Peripheral Neurotoxicity

Volume 22, Issue 3, March 2021, Pages 705-709

Qi Gui; Dapeng Li; Yan Zhuge; Chengcheng Xu

• View Article
• PDF 286.81 K

Association of Voltage-Gated Sodium Channel Genetic Polymorphisms with Oxaliplatin-Induced Chronic Peripheral Neuropathy in South Indian Cancer Patients

Volume 18, Issue 11, November 2017, Pages 3157-3165

Sreenivasulu palugulla; Dimpal N Thakkar; Smita Kayal; Sunil Narayan; Steven Dkhar

• View Article
• PDF 359.4 K

Prognostic Nomogram for Advanced Hepatocellular Carcinoma Treated with FOLFOX 4

Volume 18, Issue 5, May 2017, Pages 1225-1232

Shukui Qin; Xinji Zhang; Wei Guo; Jian Feng; Tianyi Zhang; Lichuang Men; Jia He

• View Article
• PDF 495.76 K

Prevalence of Oxaliplatin-induced Chronic Neuropathy and Influencing Factors in Patients with Colorectal Cancer in Iran

Volume 16, Issue 17, December 2015, Pages 7603-7606

• View Article
• PDF 339.59 K

Ki-67 Can Predict the Response to the Gemcitabine, Oxaliplatin And L-asparaginase Regimen (GELOX) and Prognosis in Patients with Nasal Natural Killer/T-cell Lymphoma

Volume 16, Issue 11, November 2015, Pages 4515-4520

• View Article
• PDF 1.28 M

Second-Line Capecitabine and Oxaliplatin Combination for Gemcitabine-Resistant Advanced Pancreatic Cancer

Volume 15, Issue 17, December 2014, Pages 7119-7123

• View Article
• PDF 586.62 K

The XPD Lys751Gln Polymorphism has Predictive Value in Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy: a Systemic Review and Meta-analysis

Volume 15, Issue 22, December 2014, Pages 9699-9706

• View Article
• PDF 1.33 M

The ERCC1 C118T Polymorphism Predicts Clinical Outcomes of Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy: a Meta-analysis Based on 22 Studies

Volume 15, Issue 19, December 2014, Pages 8383-8390

• View Article
• PDF 1.3 M

Phase II Clinical Study on the GEMOX Regimen as Secondline Therapy for Advanced Ovarian Cancer

Volume 14, Issue 6, June 2013, Pages 3949-3953

• View Article
• PDF 480.71 K

Comparative Assessment of Skin and Subcutaneous Toxicityin Patients of Advanced Colorectal Carcinoma Treated withDifferent Schedules of FOLFOX

Volume 14, Issue 3, March 2013, Pages 1781-1786

• View Article
• PDF 695.28 K

Oxaliplatin Sensitizes OS Cells to TRAIL-induced Apoptosis Via Down-regulation of Mcl1

Volume 13, Issue 7, July 2012, Pages 3477-3481

• View Article
• PDF 705.39 K

Effect of Tissue Factor on Invasion Inhibition and Apoptosis Inducing Effect of Oxaliplatin in Human Gastric Cancer Cell

Volume 13, Issue 5, May 2012, Pages 1845-1849

• View Article
• PDF 719.16 K

Hypersensitivity Reactions to Oxaliplatin: Clinical Features and Risk Factors in Koreans

Volume 13, Issue 4, April 2012, Pages 1209-1215

• View Article
• PDF 351.27 K

Adjuvant Modified FOLFOX-4 in Patients with Stage III Rectum Adenocarcinoma

Volume 12, Issue 4, April 2011, Pages 967-970

• View Article
• PDF 333.55 K